Hookipa Pharma (HOOK) to Release Quarterly Earnings on Thursday

Hookipa Pharma (NASDAQ:HOOK) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $6.50 million for the quarter.

Hookipa Pharma Price Performance

Hookipa Pharma stock opened at $1.25 on Wednesday. The company has a market cap of $15.07 million, a PE ratio of -0.34 and a beta of 0.71. The company has a fifty day moving average price of $1.72 and a two-hundred day moving average price of $2.80. Hookipa Pharma has a 12 month low of $1.11 and a 12 month high of $10.50.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on HOOK shares. JMP Securities cut their price objective on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 21st. Royal Bank of Canada cut Hookipa Pharma from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $48.00 to $2.00 in a research note on Friday, December 20th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Hookipa Pharma in a research note on Friday, January 10th.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.